Xarelto (rivaroxaban) is a blood thinner intended to reduce the risk of stroke by helping to prevent the formation of blood clots and their complications. Janssen Pharmaceuticals, a Johnson & Johnson company, received several U.S. Food and Drug Administration approvals since 2011 to market Bayer-made Xarelto for the following purposes:
- To reduce the risk of deep vein thrombosis, or DVT, and pulmonary embolism, or PE, that might occur following knee replacement or hip replacement surgery
- To actually treat DVT and PE and to reduce their recurrence following initial treatment
- To reduce the risk of stroke in people who have a type of abnormal heart rhythm called nonvalvular atrial fibrillation
Why Are Xarelto Lawsuits Being Filed?
Unfortunately, Xarelto has been linked to serious, sometimes fatal, bleeding. Making matters worse, there is no antidote to stop Xarelto bleeding.
How Do I Know If I Am Having A Serious Reaction To Xarelto?
Any patient who develops unexpected or long-lasting bleeding should contact his or her physician. The drug's FDA-approved medication guide lists the following red flags:
- Nosebleeds that happen often
- Unusual bleeding from the gums
- Menstrual bleeding that is heavier than normal or vaginal bleeding
- Bleeding that is severe or you cannot control
- Red, pink or brown urine
- Bright red or black stools (looks like tar)
- Cough up blood or blood clots
- Vomit blood or your vomit looks like "coffee grounds"
- Headaches, feeling dizzy or weak
- Pain, swelling, or new drainage at wound sites
For the injured, prompt medical attention is urgent. Another priority is the pursuit of justice for injuries that can be linked to taking Xarelto.
For a free confidential consultation, regardless of the state you live in, contact Reich & Binstock online or by calling toll free 1-866-LAW-2400.
Xarelto Frequently Asked Health Questions
What should I do if I am taking Xarelto?
Ensure that you contact your physician if you experience any of the symptoms of serious bleeding listed above as well as any other symptoms about which a professional cautions. Additionally, the National Library of Medicine advises Xarelto patients to "be careful to avoid injuries that could cause bleeding. Stay away from rough sports or other situations where you could be bruised, cut, or hurt. Brush and floss your teeth gently. Be careful when using sharp objects, including razors and fingernail clippers. Avoid picking your nose. If you need to blow your nose, blow it gently."
Should I stop taking Xarelto?
Do not stop taking Xarelto without discussing it with the prescribing physician. Stopping the use of Xarelto increases the risk of stroke. Your physician may prescribe a different blood thinner.
Are there alternatives to Xarelto?
Yes. There are several blood thinners on the market that your physician may consider to help prevent the formation of a blood clot.
What kinds of blood clots are DVT and PE?
Blood clots in the veins, also known as venous thromboembolism (VTE), include deep vein thrombosis (DVT) and pulmonary embolism (PE), according to the U.S. Food and Drug Administration. DVT is the formation of a blood clot in the vein, often in the lower leg or thigh. If the clot travels to the lung, then it becomes a PE, which is a potentially fatal condition in which an artery in the lung is blocked.
Why are Xarelto lawsuits being filed?
Xarelto lawsuits are being filed by injured patients and by the family of patients who died. These lawsuits generally allege that "Xarelto causes severe bleeding and other injuries and that defendants did not adequately warn prescribing physicians or consumers of the risks associated with Xarelto," according to the U.S. Judicial Panel on Multidistrict Litigation.
The maker and marketer acted irresponsibly by not disclosing the risk of uncontrollable bleeding to patients and to health care professionals.
The JPML centralized Xarelto lawsuits before a single federal judge in the federal Eastern District of Louisiana, where the cases receive a somewhat uniform pretrial process for the convenience of the parties, witnesses and the court.
Xarelto lawsuits are also being filed in state courts, to include a mass tort docket in Pennsylvania.
Can filing a Xarelto lawsuit help me?
Yes, as long as the lawsuit is filed as soon as possible – before it is too late. When the use of a prescription drug exposes the patient to an unreasonable risk that results in serious injury, then the patient may be entitled to compensation from the companies that made and marketed that drug. Damages may be recoverable for any of the following repercussions:
- Hospitalization due to complications
- Emergency room visits
- Lost wages/income
- Emotional distress
- Severe injury
- Death of a loved one
Xarelto lawsuits may be filed now. The Xarelto attorneys at Reich & Binstock operate in all 50 states and are taking cases from everywhere in the United States.
How can Reich & Binstock help me?
Reich & Binstock specializes in pharmaceutical injury litigation such as Xarelto lawsuits. Our attorneys have specialized expertise as well as a proven track record in fighting the pharmaceutical industry for exposing patients to unreasonable and dangerous risks.
Reich & Binstock attorneys also have extensive experience in managing multidistrict litigation, or MDL, and mass tort proceedings, particularly those that involve dangerous drugs. As a result, the U.S. Judicial Panel on Multidistrict Litigation often seeks the skills, knowledge and resources our lawyers can offer to MDL committees.
If you suffered a severe bleeding injury from using Xarelto or if someone in your family suffered fatal bleeding after using Xarelto, contact one of the Xarelto attorneys at Reich & Binstock for a free consultation. Our toll-free number is 1-866-LAW-2400.
Latest Xarelto Lawsuit News
December 15, 2015: Xarelto litigation continues to mount as 2016 begins. The number of Xarelto lawsuits centralized at a Louisiana federal court stands at 2,400. Lawsuits filed at a Philadelphia state court's mass tort docket are not included in that figure.
February 9, 2015: The respected medical Journal JAMA Internal Medicine published a report citing instances in which the U.S. Food and Drug Administration uncovered "misconduct" in the way clinical trials used to test the efficacy of drugs are carried out. The agency rated eight of its 16 inspections of sites involved in a clinical trial of rivaroxaban as OAI, which stands for "official action indicated" because of irregularities. As the JAMA Internal Medicine article pointed out, "Eight of 16 FDA inspections of sites involved in a clinical trial of rivaroxaban, a novel anticoagulant, had been rated OAI. These inspections had uncovered evidence of various transgressions, such as 'systemic discarding of medical records,' unauthorized unblinding, falsification, and 'concerns regarding improprieties in randomization.' Consequently, the entire study … was deemed unreliable by the FDA."
January 22, 2015: The Philadelphia Court of Common Pleas created a mass tort docket for the filing of Xarelto lawsuits. The move ideally would eliminate duplicative discovery, preclude inconsistent rulings, and promote judicial efficiency.
December 12, 2014: The U.S. Judicial Panel on Multidistrict Litigation centralized federal Xarelto lawsuits before a single judge at U.S. District Court for the Eastern District of Louisiana. Centralization makes the pretrial process more efficient and conserves the resources of the parties, their counsel, and the judiciary.
October 15, 2014: Several plaintiffs filed a motion to consolidate Xarelto lawsuits before one federal judge. In their brief, submitted to the U.S. Judicial Panel on Multidistrict Litigation, plaintiffs argued that Bayer and Janssen left health care providers and patients in the dark. As their brief puts it, "sales representatives of Defendants provided promotional materials to prescribing physicians detailing that Xarelto is more convenient and as effective as warfarin in reducing strokes in patients with nonvalvular atrial fibrillation, as well as preventing DVT/PE in patients with prior history of DVT/PE or after undergoing hip or knee replacement surgery; however, the prescribing physicians were not adequately informed of the lack of reversal agent and risks associated with Xarelto."
January 2014: The FDA approved a Xarelto labeling change that included the language, "A specific antidote for rivaroxaban is not available." The drug, which had been on the market without such a warning since the agency approved it in 2011, earned $2 billion in global sales in 2013.